Allurion Technologies (ALUR) announced a new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry. The company signed a term sheet with a strategic partner for ex-US distribution and R&D, including a potential GLP-1 drug-eluting balloon. Allurion also submitted a protocol for a clinical trial on its program combined with a low-dose GLP-1 and reported its PMA application for the Allurion Balloon was accepted by the FDA.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR: